Nanobiotix S.A. (EPA:NANO)
3.602
-0.014 (-0.39%)
Feb 21, 2025, 5:35 PM CET
Nanobiotix Revenue
Nanobiotix had revenue of 9.29M EUR in the half year ending June 30, 2024, with 598.95% growth. This brings the company's revenue in the last twelve months to 42.20M, up 526.17% year-over-year. In the year 2023, Nanobiotix had annual revenue of 36.21M with 658.12% growth.
Revenue (ttm)
42.20M
Revenue Growth
+526.17%
P/S Ratio
3.67
Revenue / Employee
383.67K
Employees
102
Market Cap
170.75M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sanofi | 44.29B |
Sartorius Stedim Biotech | 2.78B |
bioMérieux | 3.81B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.34B |
emeis Société anonyme | 5.43B |
Nanobiotix News
- 10 days ago - Baillie Gifford's Strategic Acquisition of Nanobiotix SA Shares - GuruFocus
- 23 days ago - Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer - GlobeNewsWire
- 3 months ago - Nanobiotix gives Q3 update - Seeking Alpha
- 3 months ago - NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewsWire
- 4 months ago - NANOBIOTIX to Participate in Multiple Investor Conferences in November - GlobeNewsWire